News
CARA
0.7538
+0.49%
0.0037
Bearish Monday For Marijuana Stocks - Flower One Hldgs, SOL Glb Inv Among Top Gainers
Heritage Cannabis Holding shares closed up up at $. Cronos Group shares closed down in the last day. The company's stock closed up in the previous day. Other companies with a focus on the cannabis industry also closed down in the past week.
Benzinga · 1d ago
Weekly Report: what happened at CARA last week (0513-0517)?
Weekly Report · 1d ago
Cannabis Stock Movers For May 17, 2024
Shares of Elixinol Wellness closed up at $. Australis Capital shares closed down in the last week. Cronos Group and other cannabis companies closed down in the past week. The shares of Cronos and others closed down at $1.06.
Benzinga · 4d ago
Cannabis Stock Gainers And Losers From May 16, 2024
Flower One shares closed up at $1e-05. Aurora Cannabis and Canopy Gwth share prices closed up. Cronos Group shares closed down in the last week. The company's shares are down in the past month. The shares of several other companies closed down.
Benzinga · 5d ago
Cara Therapeutics Price Target Maintained With a $3.60/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Cara Therapeutics, Maintains $3.6 Price Target
Benzinga · 6d ago
Cara Therapeutics: A Strong Buy on Promising Notalgia Paresthetica Treatment
Analyst Oren Livnat of . Wainwright reiterated a Buy rating on Cara Therapeutics (CARA) Cara’s oral difelikefalin (DFK) in treating notalgia paresthetica (NP), a condition with no FDA-approved therapies currently available.
TipRanks · 6d ago
In-Depth Examination Of 5 Analyst Recommendations For Cara Therapeutics
Cara Therapeutics underwent analysis by 5 analysts in the last quarter. The company is a development-stage biotechnology company involved in the development of novel drugs to treat pain and pruritus. Cara Therapeutic has an average 12-month price target of $. The firm's revenue growth lags behind its peers in the Health Care sector.
Benzinga · 05/14 16:01
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Iterum Therapeutics (ITRM) and Cara Therapeutics (CARA)
TipRanks · 05/14 15:20
Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham
Dow Jones · 05/14 15:16
Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
Benzinga · 05/14 15:07
Cara Therapeutics: A Buy Rating Ahead of Key Oral Difelikefalin Trial Results
TipRanks · 05/14 11:35
Piper Sandler Sticks to Their Hold Rating for Cara Therapeutics (CARA)
TipRanks · 05/14 11:21
Cara Therapeutics (CARA) Gets a Buy from Stifel Nicolaus
TipRanks · 05/14 11:06
Cara Therapeutics, Inc. Q1 2024 Financial Report: Condensed Consolidated Balance Sheets, Statements, and Disclosures
Press release · 05/14 04:24
CARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024
Cara Therapeutics reported earnings per share of -56 cents for the first quarter of 2024. The company reported revenue of $ million. This was better than the analyst estimate for revenue of $ million. Cara Therapeutic just reported results for the first quarter of 2024.
Investorplace · 05/14 00:55
Cara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Cara Therapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 56 cents per share. Revenue fell to $ million from a year ago; analysts expected a loss of $ million. The average analyst rating on the company's shares is "buy"
Reuters · 05/13 21:22
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/13 21:10
Cara Therapeutics GAAP EPS of -$0.56 misses by $0.17, revenue of $2.14M beats by $0.45M
Cara Therapeutics GAAP EPS of -$ misses by $ , revenue of $ beats by $ in Q1. Cash, cash equivalents and marketable securities at March 31, 2024 totaled $ million. Cara expects to have sufficient cash to fund its operating plan into 2026.
Seeking Alpha · 05/13 20:05
BRIEF-Cara Therapeutics Q1 Revenue USD 1.8 Million
Reuters · 05/13 20:01
More
Webull provides a variety of real-time CARA stock news. You can receive the latest news about Cara Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About CARA
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.